This article reviews case reports for 58 suspected impaired driving cases that were positive for the synthetic cannabinoids AB-CHMINACA or AB-PINACA. All cases were submitted to the Washington State Patrol Toxicology Laboratory in 2014 from either Washington State or State of Alaska law enforcement agencies. The population of drivers was predominantly male (95%), with a mean age of 28 years (range, 18-61 years). The range of blood concentrations was 0.6 ->10 ng/mL for AB-CHMINACA (N 5 33) and 0.6 -41.3 ng/mL for AB-PINACA (N 5 25). Drug Recognition Expert exams were performed in 10 cases for each AB-CHMINACA and AB-PINACA. Horizontal gaze nystagmus was observed in 50 and 60% of the cases, respectively. Overall, several physiological indicators varied from those typically observed with marijuana use. The majority of these cases had very poor driving; subjects were involved in an accident, found passed out in a vehicle or were called in as a suspected impaired driver. Slurred speech, confusion, lack of coordination/ dexterity and lethargy were commonly observed.
Introduction
Synthetic cannabinoids (SCs) are chemically synthesized compounds that are prepared and used to mimic the effects of marijuana (1) . The Drug Enforcement Administration (DEA) reports that the prevalence of SCs began to rise in the United States in 2009 (1) . SCs are marketed as legal drugs and are commonly known as 'Spice' products. There are hundreds of potential SCs that can be manufactured; typically, once a specific compound is regulated by the DEA a new compound will hit the market (2) .
On 19 December 2014, the DEA submitted a letter of intent to place three compounds into the Controlled Substances Act as Schedule I on a temporary basis: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and [1-(5-fluoropentyl)-1H-indazole-3-yl](naphthalene-1-yl)methanone (THJ-2201) (1) . This order was granted on 30 January 2015 (3).
AB-CHMINACA was first synthesized by Pfizer, Inc.; a patent was submitted in 2009 (4) . The DEA reported the first encounter of AB-CHMINACA in March 2014, and AB-PINACA in June 2013 (3) .
At the Washington State Patrol Toxicology Laboratory, the results of testing for SCs have followed the trend of DEA regulation (see Figure 1 ). In 2012, the laboratory reported 29 instances of either JWH-018, JWH-073, JWH-081, JWH-122, JWH-210 and/ or JWH-250. JWH-018, JWH-073 and JWH-200 were placed into Schedule I in March 2011. In 2013, the laboratory reported only four instances of JWH-018, JWH-022 and/or JWH-081. The more prevalent SCs observed in 2013 were XLR-11 (N ¼ 24) and UR-144 (N ¼ 13). UR-144 and XLR-11 were regulated in May 2013. By 2014, the laboratory reported only four instances of UR-144 or XLR-11. As the prevalence of these compounds diminished, AB-CHMINACA and AB-PINACA appeared. In 2014, these compounds represented 94% of the SCs detected by the laboratory. This study includes all samples submitted to the Washington State Toxicology Laboratory in 2014 that were positive for either AB-CHMINACA or AB-PINACA. Information is provided regarding concentrations of drugs observed, driving behavior and results of all Drug Recognition Expert (DRE) examinations that were performed.
Methods
Blood samples from suspected impaired driving cases are submitted to the laboratory from either Washington State or State of Alaska law enforcement agencies. Blood is collected in 10 mL Vacutainer w grey test tubes containing 100 mg sodium fluoride and 20 mg potassium oxalate. Samples are stored at 2 -88C until analysis.
All samples are screened for volatiles using headspace gas chromatography with flame ionization detection. Samples are subsequently screened for the following drug classes using the Enzyme Multiplied Immunoassay Technique (EMIT): amphetamines (cutoff concentration 200 ng/mL), barbiturates (100 ng/mL), benzodiazepines (100 ng/mL), cannabinoids (10 ng/mL), cocaine metabolite (100 ng/mL), methadone (100 ng/mL), opiates (20 ng/mL), phencyclidine (10 ng/mL) and tricyclic antidepressants (100 ng/mL). Additional testing may be performed based on case history or EMIT results. The majority of cases in this study (N ¼ 44) underwent a liquid -liquid alkaline extraction with n-butyl chloride followed by back extraction into hydrochloric acid before analysis on gas chromatography/mass spectrometry (GC -MS) coupled to a nitrogen phosphorus detector. Confirmatory tests of initial screening results were performed using liquid chromatography -tandem mass spectrometry or GC -MS.
In cases where SCs are suspected, samples are sent to AIT Laboratories in Indianapolis, IN. The number of compounds screened for in the SCs panel increased throughout 2014. At a minimum all cases were analyzed for: 5F-PB -22, AB-PINACA,  ADB-PINACA, AM-2201, BB-22, C1-2201, JWH-015, JWH-018,  JWH-019, JWH-073, JWH-122, JWH-081, JWH-210, JWH-250,  MAM-2201, PB-22, UR-144 and XLR-11. The panel was expanded  to eventually include 5F-AB-PINACA, 5F-ADB-PINACA, 5F-AMB,  5F-NNEI, 5F-THJ, AB-CHMINACA, AB-FUBINACA, ADB-FUBINACA,  AMB, EAM-2201, FAB-144, FDU-PB-22, FUB-AMB, FUB-PB-22,  M-144, MN18, NNEI, SDB-006, THJ, THJ-018, THJ-2201 and  XLR12. See Table I for case specifics.
Samples are tested for SCs via liquid chromatography tandem mass spectrometry following a liquid -liquid extraction using bicarbonate buffer ( pH 10.2) and hexane -ethyl acetate (98:2) (5). Separations were performed using a Waters Acquity UPLC BEH 1.7 mM, 2.1 Â 100 mm column, maintained at 608C and eluted at a constant flow rate of 0. Validation testing for the compounds AB-CHMINACA and AB-PINACA demonstrated that they were linear over the concentration range of 0.2 -10 ng/mL, with a limit of detection of 0.1 ng/mL and a limit of quantitation of 0.2 ng/mL. Within run and between run accuracy for both analytes at two concentrations, 1.5 and 6 ng/mL, did not exceed 15%. Matrix effects were examined at three concentrations (1.5, 10 and 16 ng/ mL). All results were ,10% CV. No exogenous interferences were detected, and carryover was not detected at 100 ng/mL. See Table II for method validation results.
Results
In 2014, the laboratory received 6,815 submissions for Driving Under the Influence (DUI) and DRE cases. Of these, 58 cases tested positive for AB-CHMINACA or AB-PINACA; however, this number is not a true measure of prevalence of these compounds. As there is no in-house screening method for SCs, the decision to send the case sample to an external laboratory for testing may be based on information provided in the case history, request of law enforcement agency or what other drugs have been detected in the case.
The positive cases were predominantly male (95%), with a mean age of 28 years (range, 18 -61 years). Of the 33 cases that were positive for AB-CHMINACA, 10 were DRE cases and 23 were Driving Under the Influence (DUI) cases. Of the 25 cases that were positive for AB-PINACA, 10 were DRE and 15 were DUI cases. Sixteen cases had drugs present other than AB-CHMINACA or AB-PINACA. Of the multi-drug cases, nine were positive for other SCs and four had other active drugs present that could contribute to impairment. See Table I for a listing of drugs present in all reported cases. The brief case histories that were provided for each case had several commonalities-the most common reason provided for initiation of a stop was a 911 call to report an erratic driver/possible DUI (AB-CHMINACA, N ¼ 8; AB-PINACA, N ¼ 7). The reports usually consisted of a driver with extreme lane travel with near collisions. The second most common case history involved the arresting officer finding the individual slumped over the wheel or unconscious in the vehicle upon initial contact (AB-CHMINACA, N ¼ 9; AB-PINACA, N ¼ 4). Often the drivers would be stopped in a roadway (N ¼ 5), and usually the vehicle would still be running. There were also numerous responses to collisions, typically a one vehicle collision into a parked vehicle, the ditch, and in one instance, a house (AB-CHMINACA, N ¼ 5; AB-PINACA, N ¼ 6). There were two medical emergency calls for seizure-like behavior for drivers positive for AB-CHMINACA. Eleven cases had no case history provided.
The DRE data from these cases also revealed some trends. Of the 20 DRE cases, the DRE officer noted bloodshot eyes (80%), watery eyes (55%) and droopy eyelids (68%). Horizontal gaze nystagmus (HGN) was observed in 50 and 60% of AB-CHMINACA and AB-PINACA cases, respectively. It is interesting to note that HGN was observed in the cases with the lowest concentrations of either drug, but as the concentrations increased for each drug, HGN was not observed. This is in contrast to ethanol where, as the concentration increases, the number of clues observed for HGN increases (6) . At high ethanol concentrations for an individual, vertical gaze nystagmus (VGN) will also be observed. Lack of convergence was observed in 70% of the AB-PINACA cases, but only in 30% of the AB-CHMINACA cases. Pulse was elevated (.90 beats per minute) for more cases of AB-CHMINACA compared with AB-PINACA, but low blood pressure (,120/70 mm Hg) was observed equally. Detailed observations of the DRE examination for each case are summarized in Tables III and IV .
Case histories
In several cases, the laboratory received multiple submissions for an individual due to repeated arrests on different days. The case histories for three of these individuals are discussed in more detail below.
Subject 1
The laboratory received evidence for one 22-year-old male from five different arrests during a 5-month period. The subject was a member of the U.S. Army stationed in western Washington. The first submission was from an incident on 2 March 2014. The subject was contacted parked on the side of the road, facing the wrong way, with his vehicle running. The subject was looking at his phone, and said he was lost. He appeared confused, had extremely slurred speech, was shaking and had dilated pupils and a distant stare. He had zero clues on HGN, five clues on the walk and turn (WAT) test and three clues on the one leg stand (OLS) test. The result of testing was 27.8 ng/mL AB-PINACA. The second incident occurred on 7 May 2014. The subject was contacted due to his vehicle being stopped in the roadway. The subject was unable to stand on his own. The result of testing was 10 ng/mL AB-CHMINACA. The third incident occurred on 10 May 2014. The subject was reported for driving erratically on a military base. The result of testing was 9.1 ng/mL AB-CHMINACA. The fourth incident occurred on 13 May 2014. The subject was found passed out in his vehicle, with the vehicle running and still in drive. The subject had very slow and lethargic movements and could not maintain balance. A full DRE examination was performed; see subject 16 in Table IV . The result of testing was 4.5 ng/mL AB-CHMINACA. The fifth incident occurred on 12 July 2014. The subject was stopped for lane travel, stopping at green lights and nearly striking other motorists. The subject admitted to Spice use in the past. No testing was performed on this submission due to changes in the requirements of warrant language in Washington State (The State may not conduct tests on a lawfully procured blood sample without first obtaining a warrant that authorizes testing and specifies the types of evidence for which the sample may be tested. State v. Martines, COA No. 69663-7-I, 21 July 2014).
Subject 2
A 38-year-old male was arrested twice at the same ferry terminal. The first incident occurred on 10 May 2014. Initial contact with law enforcement occurred after a 911 call from witnesses who believed the subject to be impaired. The subject was not in his vehicle at the time of arrest, but was in a restaurant adjacent to the ferry terminal. He was leaning up against the restaurant counter and unable to maintain his balance. He had thick/ slurred speech and bloodshot eyes. The subject had two clues on HGN, and three clues on OLS; the WAT test was not administered for the subject's safety. The result of testing was 5.9 ng/mL AB-CHMINACA. The second incident occurred on 10 August 2014. The subject was holding up the ticket line at the ferry terminal and briefly fell asleep while at the ticket booth. After leaving the ticket booth area, the subject passed out at the wheel, with his vehicle blocking the roadway and sidewalk. The first officer that had contact with the subject observed him to be sweating profusely, lethargic, confused and had food smeared on his face. The subject had difficulty maintaining his balance and kept dropping his phone and e-cigarette. A full DRE examination was performed; see Subject 12 in Table IV . The result of testing was 2.3 ng/mL AB-CHMINACA.
Subject 3
A 19-year-old male was arrested for two separate suspected impaired driving incidents. The first incident occurred on 2 December 2014. The subject was reported asleep at the wheel, with his vehicle parked in the roadway. When approached by law enforcement, the subject initially attempted to elude but eventually stopped. He admitted to smoking Spice. His speech was observed to be slow and very slurred. No HGN was observed. The WAT and OLS were not performed due to the level of impairment observed; the subject was swaying badly and was unstable on his feet. Testing results were 0.05 mg/L diphenhydramine and 7.1 ng/mL of AB-CHMINACA. The second incident occurred on 12 December 2014, when the subject was stopped for poor driving. A full DRE examination was performed; see Subject 18 in Table IV . The results of testing were 0.05 mg/L diphenhydramine and 7.1 ng/mL AB-CHMINACA.
Discussion
Although SCs are developed to mimic the effects of marijuana, the reported physiological and DRE indicators for SCs can vary greatly from classic marijuana use (see Table V ). Marijuana typically causes an increased heart rate and blood pressure, HGN and Pupil size was measured in three light conditions: room light, near total darkness, and direct light. D, dilated, C, constricted, NORM, normal. If only one letter present, the eyes were the same for all three light conditions.
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VGN are not present, lack of convergence is observed and pupils are normal to dilated (8) . In contrast, for this current study of AB-CHMINACA and AB-PINACA cases, it was observed that HGN was present in 50 -60% of the cases, blood pressure was lowered in 80% of the cases and lack of convergence was not always present. In addition, eyelid tremors, which are anecdotally a common indicator for marijuana use, were only observed in 22% of AB-PINACA and 10% of AB-CHMINACA cases.
There are several reviews that discuss the effects of SCs. For the early JWH-type compounds, case reports for seven individuals included signs and symptoms of sedation, confusion, dilated pupils, motor incoordination and delayed reactions (9) . Another study examined the physiological indicators in 12 DRE cases that were positive for JWH-type variants or AM-2201 (10). These findings indicated lack of HGN or VGN, normal to elevated pulse rate, elevated blood pressure and dilated pupils. A study of 18 cases positive for XLR-11 or UR-144 found 55% to have HGN present at two or more clues, elevated blood pressure and pulse and lack of convergence present (11) .
Performance on the standardized field sobriety divided attention tests, WAT and OLS, were good indicators of impairment. A score of 2 out of 8 clues on the WAT and 2 out of 4 clues on the OLS are consistent with impairment (6) . For the WAT, 70% of AB-PINACA and 50% of AB-CHMINACA cases scored 2 or more clues. For the OLS, 78% of AB-PINACA and 56% of AB-CHMINACA cases scored 2 or more clues. These findings are consistent with studies that measured the effectiveness of the WAT and OLS to identify impaired driving due to marijuana (12, 13) .
There are limitations to the results that are presented here due to the lack of uniformity in the testing that was performed for all of the cases. The number of compounds that were screened for in the SCs panel increased over the course of the year several times. However, the impact for this change seems to be minimal. Of the 22 compounds that were added to the testing panel, only one was ever detected besides AB-CHMINACA and AB-PINACA: this was 5F-AB-PINACA in Case 15. AB-CHMINACA was not screened for in four cases, however, in the remaining 54 cases, AB-PINACA and AB-CHMINACA were never detected in combination.
In addition, 14 cases did not have a full drug screen for alkaline drugs performed. However, based on results from the remaining cases, it appears usage of SCs is typically not co-administered with other recreational drugs.
Four of the DRE cases had other drugs present that may have contributed to the observed effects. Two of these cases were positive for other SCs besides AB-CHMINACA or AB-PINACA. The reported effects still support that SCs may produce atypical effects compared with marijuana use. D9-tetrahydrocannabinol (THC) was detected in one case, however, THC does not typically result in HGN. The observation of six clues in the HGN test for this case still supports that AB-CHMINACA is the likely source of this effect. The fourth case had the presence of diphenhydramine, a central nervous system depressant; presence of this drug should be taken into consideration for interpretation of the results.
There are two cannabinoid receptors that have been identified, CB1 and CB2. CB1 is mainly located in the brain and is responsible for the impairing effects of marijuana (14) . The binding affinity (K i ) of THC to the CB1 receptor is 41 nM (15) . A review of reported binding affinities for numerous SCs demonstrates a wide range of values, from 0.06 -1678 nM (16) . AB-CHMINACA was reported in the 2009 patent by Pfizer Inc. to have a K i toward the CB1 receptor of 0.5 nM (4). In addition to the K i , it is also important to determine the intrinsic activity (measure of potency and efficacy) of the compounds at the CB1 receptor. THC is often classified as a partial to full agonist, while many of the SCs are full agonists (17) . These stronger binding affinities help to explain why the majority of SCs have a greater potency than marijuana as demonstrated in the increased effects of impairment. It can also explain why there are differences in clinical indicators between marijuana and SCs and also amongst variants of SCs.
Karinen et al. published a review of reported blood concentrations for various SCs. There were 41 blood cases with 14 different SCs detected. The blood concentrations ranged from 0.07 to 24.5 ng/mL (18) . In 2013, concentrations of THC detected in blood in impaired driving cases from our laboratory ranged from 1 to 77 ng/mL with a mean of 7.2 ng/mL (19) . The majority of the concentrations for AB-CHMINACA and AB-PINACA observed in this study were ,10 ng/mL. However, the case histories that were provided indicated apparent and severe impairment of the individual, even at these low concentrations. The binding affinities and reports of blood concentrations support that SCs are potent agonists of the CB1 receptor.
There is no information regarding the metabolism or other pharmacokinetic parameters such as half-life for AB-CHMINACA or AB-PINACA. For many of these cases, the subject admitted to smoking just prior to driving or during the act of driving. With inhalation as the route of absorption, the effects have a very fast onset. There was little information provided regarding the time of blood draw compared with time of initial contact from law enforcement, or about the user's history with the drug. The rapid development of novel SCs and their placement into mainstream use on a rotating annual basis challenges the analytical ability of detecting these drugs. However, as this study and others have demonstrated, impairment from SCs can be profound. Toxicology laboratories need to be aware of the limitations in their scope of testing and if provided case histories with impairment that do not comport with the toxicology testing, consider that SCs may be present.
